表紙
市場調查報告書

無針頭藥物輸送設備的全球市場:2020年∼2024年

Needle-free Drug Delivery Devices Market by Product and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 517144
出版日期 內容資訊 英文 152 Pages
訂單完成後即時交付
價格
無針頭藥物輸送設備的全球市場:2020年∼2024年 Needle-free Drug Delivery Devices Market by Product and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年12月24日內容資訊: 英文 152 Pages
簡介

全球無針頭藥物輸送設備市場上,慢性疾病的盛行率增加,新產品銷售的增加,策略性聯盟的增加等成為成長促進因素,在預測期間內預計將以4%以上的年複合成長率擴大。但,產品的頻繁回收,藥物和設備的組合產品相關的嚴格法規,及無針頭藥物輸送設備相關的高成本等要素,可能妨礙在預測期間內無針頭藥物輸送設備產業的成長。

本報告提供全球無針頭藥物輸送設備市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 價值鏈分析
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模及預測(2019年∼2024年)
  • 市場預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2019年∼2024年)
  • 吸入器
  • 經皮吸收貼片
  • 噴射注射器
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 無針頭藥物輸送設備的技術進步
  • 無針頭藥物輸送設備開發的研究與資金籌措
  • 政府的配合措施增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • 3M Co.
  • Antares Pharma Inc.
  • Becton, Dickinson and Co.
  • Enesi Pharma Ltd.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Mylan NV
  • Novartis AG
  • PharmaJet Inc.
  • Valeritas Holdings Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR40749

About this market

Technavio's needle-free drug delivery devices market analysis considers sales from inhalers, transdermal patches, and jet injectors. Our study also finds the sales of needle-free drug delivery devices in Asia, Europe, North America, and ROW. In 2019, the inhalers segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high incidence of asthma will play a significant role in the inhalers segment to maintain its market position. Also, our global needle-free drug delivery devices market report looks at factors such as the increasing prevalence of chronic disease, rising number of new product launches, and the growing number of strategic alliances. However, frequent product recalls, stringent regulations associated with drug-device combination products, and high costs associated with needle-free drug delivery devices may hamper the growth of the needle-free drug delivery devices industry over the forecast period.

Overview

Increasing prevalence of chronic diseases

Chronic diseases such as diabetes, especially type 1 diabetes is on the rise. According to the OECD, in 2017, about 600 children per 100,000 children had type 1 diabetes in Finland. With growing pollution and respiratory infections, instances of asthma have also dramatically increased. Physicians use needle-free drug delivery devices to administer insulin to children with type 1 diabetes. These devices also prove to be quite effective in the immediate administration of asthmatic medications. Needle-free drug delivery devices administer drugs through the skin of patients either by using shock waves or as a pressure generated by gas or electrophoresis. With the increasing prevalence of various chronic diseases such as diabetes and asthma, the need for needle-free drug delivery devices is increasing, which will lead to the expansion of the global needle-free drug delivery devices market at a CAGR of over 4% during the forecast period.

Technological advances in needle-free drug delivery devices

The intense competition in the market is compelling vendors to invest in R&D to expand their product portfolios. They are developing innovative and advanced devices to administer regular medications for disease management. These devices facilitate the process of drug administration for the management of several diseases and health conditions. The integration of software with needle-free drug delivery devices helps patients to adhere to their regular regimen of medication and, at the same, allows physicians to analyze the condition of their patients and improve the management of chronic respiratory diseases, such as asthma. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global needle-free drug delivery devices market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global needle-free drug delivery devices market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading needle-free drug delivery devices manufacturers, that include 3M Co., Antares Pharma Inc., Becton, Dickinson and Co., Enesi Pharma Ltd., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Mylan NV, Novartis AG, PharmaJet Inc., and Valeritas Holdings Inc.

Also, the needle-free drug delivery devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Value chain analysis
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Inhalers - Market size and forecast 2019-2024
  • Transdermal patches - Market size and forecast 2019-2024
  • Jet injectors - Market size and forecast 2019-2024
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Technological advances in needle-free drug delivery devices
  • Research and funding for development of needle-free drug delivery devices
  • Increasing government initiatives

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • 3M Co.
  • Antares Pharma Inc.
  • Becton, Dickinson and Co.
  • Enesi Pharma Ltd.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Mylan NV
  • Novartis AG
  • PharmaJet Inc.
  • Valeritas Holdings Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Global healthcare equipment market
  • Exhibit 02: Segments of global healthcare equipment market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendors: Key offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Product - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Inhalers - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Rate of hospital admissions for asthma and COPD (number of people per 100,000 population)
  • Exhibit 22: Inhalers - Year-over-year growth 2020-2024 (%)
  • Exhibit 23: Transdermal patches - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 24: Transdermal patches - Year-over-year growth 2020-2024 (%)
  • Exhibit 25: Jet injectors - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 26: Jet injectors - Year-over-year growth 2020-2024 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2019-2024 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 33: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 35: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 37: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Estimated cases of children with type 1 diabetes 2017 (per 100,000 children)
  • Exhibit 42: Product launch
  • Exhibit 43: Strategic alliances
  • Exhibit 44: Product recalls
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: 3M Co. - Vendor overview
  • Exhibit 52: 3M Co. - Business segments
  • Exhibit 53: 3M Co. - Organizational developments
  • Exhibit 54: 3M Co. - Geographic focus
  • Exhibit 55: 3M Co. - Segment focus
  • Exhibit 56: 3M Co. - Key offerings
  • Exhibit 57: 3M Co. - Key customers
  • Exhibit 58: Antares Pharma Inc. - Vendor overview
  • Exhibit 59: Antares Pharma Inc. - Business segments
  • Exhibit 60: Antares Pharma Inc. - Organizational developments
  • Exhibit 61: Antares Pharma Inc. - Geographic focus
  • Exhibit 62: Antares Pharma Inc. - Key offerings
  • Exhibit 63: Antares Pharma Inc. - Key customers
  • Exhibit 64: Becton, Dickinson and Co. - Vendor overview
  • Exhibit 65: Becton, Dickinson and Co. - Business segments
  • Exhibit 66: Becton, Dickinson and Co. - Organizational developments
  • Exhibit 67: Becton, Dickinson and Co. - Geographic focus
  • Exhibit 68: Becton, Dickinson and Co. - Segment focus
  • Exhibit 69: Becton, Dickinson and Co. - Key offerings
  • Exhibit 70: Becton, Dickinson and Co. - Key customers
  • Exhibit 71: Enesi Pharma Ltd. - Vendor overview
  • Exhibit 72: Enesi Pharma Ltd. - Business segments
  • Exhibit 73: Enesi Pharma Ltd. - Organizational developments
  • Exhibit 74: Enesi Pharma Ltd. - Key offerings
  • Exhibit 75: Enesi Pharma Ltd. - Key customers
  • Exhibit 76: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 77: GlaxoSmithKline Plc - Business segments
  • Exhibit 78: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 79: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 80: GlaxoSmithKline Plc - Segment focus
  • Exhibit 81: GlaxoSmithKline Plc - Key offerings
  • Exhibit 82: GlaxoSmithKline Plc - Key customers
  • Exhibit 83: Inovio Pharmaceuticals Inc. - Vendor overview
  • Exhibit 84: Inovio Pharmaceuticals Inc. - Business segments
  • Exhibit 85: Inovio Pharmaceuticals Inc. - Organizational developments
  • Exhibit 86: Inovio Pharmaceuticals Inc. - Key offerings
  • Exhibit 87: Inovio Pharmaceuticals Inc. - Key customers
  • Exhibit 88: Mylan NV - Vendor overview
  • Exhibit 89: Mylan NV - Product segments
  • Exhibit 90: Mylan NV - Organizational developments
  • Exhibit 91: Mylan NV - Geographic focus
  • Exhibit 92: Mylan NV - Segment focus
  • Exhibit 93: Mylan NV - Key offerings
  • Exhibit 94: Mylan NV - Key customers
  • Exhibit 95: Novartis AG - Vendor overview
  • Exhibit 96: Novartis AG - Business segments
  • Exhibit 97: Novartis AG - Organizational developments
  • Exhibit 98: Novartis AG - Geographic focus
  • Exhibit 99: Novartis AG - Segment focus
  • Exhibit 100: Novartis AG - Key offerings
  • Exhibit 101: Novartis AG - Key customers
  • Exhibit 102: PharmaJet Inc. - Vendor overview
  • Exhibit 103: PharmaJet Inc. - Business segments
  • Exhibit 104: PharmaJet Inc. - Organizational developments
  • Exhibit 105: PharmaJet Inc. - Key offerings
  • Exhibit 106: PharmaJet Inc. - Key customers
  • Exhibit 107: Valeritas Holdings Inc. - Vendor overview
  • Exhibit 108: Valeritas Holdings Inc. - Business segments
  • Exhibit 109: Valeritas Holdings Inc. - Organizational developments
  • Exhibit 110: Valeritas Holdings Inc. - Key offerings
  • Exhibit 111: Valeritas Holdings Inc. - Key customers
  • Exhibit 112: Validation techniques employed for market sizing
  • Exhibit 113: Definition of market positioning of vendors